{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:13:51Z","timestamp":1792826031989,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":586,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Early-phase clinical trials using oral inhibitors of MEK, the mitogen-activated protein kinase kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1)-associated tumors, particularly progressive low-grade gliomas and plexiform neurofibromas. Given this potential of MEK inhibition as an effective medical therapy, the use of targeted agents in the NF1 population is likely to increase substantially. For clinicians with limited experience prescribing MEK inhibitors, concern about managing these treatments may be a barrier to use. In this manuscript, the Clinical Care Advisory Board of the Children's Tumor Foundation reviews the published experience with MEK inhibitors in NF1 and outlines recommendations for side-effect management, as well as monitoring guidelines. These recommendations can serve as a beginning framework for NF providers seeking to provide the most effective treatments for their patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1) clinical care is on the cusp of a transformative shift. With the success of recent clinical trials using MEK inhibitors, an increasing number of NF1 patients are being treated with MEK inhibitors for both plexiform neurofibromas and low-grade gliomas. The use of MEK inhibitors is likely to increase substantially in NF1. Given these changes, the Clinical Care Advisory Board of the Children's Tumor Foundation has identified a need within the NF1 clinical community for guidance for the safe and effective use of MEK inhibitors for NF1-related tumors. This article provides a review of the published experience of MEK inhibitors in NF1 and provides recommendations for monitoring and management of side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0069","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:25:11Z","timestamp":1586453111000},"page":"e1109-e1116","source":"Crossref","is-referenced-by-count":106,"title":["The Use of MEK Inhibitors in Neurofibromatosis Type 1\u2013Associated Tumors and Management of Toxicities"],"prefix":"10.1093","volume":"25","author":[{"given":"Laura J.","family":"Klesse","sequence":"first","affiliation":[{"name":"University of Texas Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather B.","family":"Radtke","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, USA"},{"name":"Children's Tumor Foundation, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tena","family":"Rosser","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Children's Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schorry","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ullrich","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viskochil","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Knight","sequence":"additional","affiliation":[{"name":"Children's Tumor Foundation, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Yohay","sequence":"additional","affiliation":[{"name":"NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2021122510445623600_onco13310-bib-0001","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"2021122510445623600_onco13310-bib-0002","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/jmg.26.11.712","article-title":"A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling","volume":"26","author":"Huson","year":"1989","journal-title":"J Med Genet"},{"key":"2021122510445623600_onco13310-bib-0003","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510445623600_onco13310-bib-0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510445623600_onco13310-bib-0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510445623600_onco13310-bib-0006","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","article-title":"Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): A randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Schadendorf","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122510445623600_onco13310-bib-0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: Next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"2021122510445623600_onco13310-bib-0008","first-page":"750","article-title":"Pediatric low-grade gliomas: Implications of the biologic era","volume":"19","author":"Packer","year":"2017","journal-title":"Neuro Oncol"},{"key":"2021122510445623600_onco13310-bib-0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/brain\/awg016","article-title":"Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients","volume":"126","author":"Guillamo","year":"2003","journal-title":"Brain"},{"key":"2021122510445623600_onco13310-bib-0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","article-title":"Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas","volume":"104","author":"Helfferich","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122510445623600_onco13310-bib-0011","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","article-title":"Progression-free survival in children with optic pathway tumors: Dependence on age and the quality of the response to chemotherapy--Results of the first French prospective study for the French Society of Pediatric Oncology","volume":"21","author":"Laithier","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122510445623600_onco13310-bib-0012","first-page":"1257","article-title":"A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: A population-based cohort study (CCLG CNS9702)","volume":"12","author":"Stokland","year":"2010","journal-title":"Neuro Oncol"},{"key":"2021122510445623600_onco13310-bib-0013","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/cncr.29987","article-title":"Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group","volume":"122","author":"Ater","year":"2016","journal-title":"Cancer"},{"key":"2021122510445623600_onco13310-bib-0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B","article-title":"Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma","volume":"45","author":"Grill","year":"1999","journal-title":"Ann Neurol"},{"key":"2021122510445623600_onco13310-bib-0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/jmg.2010.081760","article-title":"A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations","volume":"48","author":"Sharif","year":"2011","journal-title":"J Med Genet"},{"key":"2021122510445623600_onco13310-bib-0016","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122510445623600_onco13310-bib-0017","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J Neurosurg"},{"key":"2021122510445623600_onco13310-bib-0018","doi-asserted-by":"crossref","first-page":"e27474","DOI":"10.1002\/pbc.27474","article-title":"Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma","volume":"66","author":"Knight","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2021122510445623600_onco13310-bib-0019","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"2021122510445623600_onco13310-bib-0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122510445623600_onco13310-bib-0021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"key":"2021122510445623600_onco13310-bib-0022","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"key":"2021122510445623600_onco13310-bib-0023","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"2021122510445623600_onco13310-bib-0024","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2021122510445623600_onco13310-bib-0025","first-page":"1573","article-title":"International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis","volume":"62","author":"Ferner","year":"2002","journal-title":"Cancer Res"},{"key":"2021122510445623600_onco13310-bib-0026","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","article-title":"Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1","volume":"68","author":"Ferner","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122510445623600_onco13310-bib-0027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-012-0840-5","article-title":"[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: Correlation with malignant transformation","volume":"108","author":"Tsai","year":"2012","journal-title":"J Neurooncol"},{"key":"2021122510445623600_onco13310-bib-0028","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: The Children's Hospital of Philadelphia experience, 1974-1994","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"2021122510445623600_onco13310-bib-0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","article-title":"Resection of plexiform neurofibromas in children with neurofibromatosis type 1","volume":"31","author":"Canavese","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"2021122510445623600_onco13310-bib-0030","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122510445623600_onco13310-bib-0031","article-title":"SPRINT: Phase II study of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"35","author":"Gross","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021122510445623600_onco13310-bib-0032","article-title":"NFM-06. NF106: Phase 2 trial of the MEK inhibitor PD-0325901 in adolescents and adults with NF1-related plexiform neurofibromas: An NF Clinical Trials Consortium Study","volume":"20","author":"Weiss","year":"2018","journal-title":"Neuro Oncol"},{"issue":"15","key":"2021122510445623600_onco13310-bib-0033","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)\u2013associated plexiform neurofibroma: A phase I\/IIa study","volume":"36","author":"McCowage","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21 Suppl 1","key":"2021122510445623600_onco13310-bib-0034","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"key":"2021122510445623600_onco13310-bib-0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/17425255.2016.1214710","article-title":"BRAF and MEK inhibitors in pediatric glioma: New therapeutic strategies, new toxicities","volume":"12","author":"Rizzo","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021122510445623600_onco13310-bib-0036","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"2021122510445623600_onco13310-bib-0037","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122510445623600_onco13310-bib-0038","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/DER.0000000000000358","article-title":"Bleach for atopic dermatitis","volume":"29","author":"Maarouf","year":"2018","journal-title":"Dermatitis"},{"key":"2021122510445623600_onco13310-bib-0039","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2133.2010.09906.x","article-title":"Periungual and subungual pyogenic granuloma","volume":"163","author":"Piraccini","year":"2010","journal-title":"Br J Dermatol"},{"key":"2021122510445623600_onco13310-bib-0040","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122510445623600_onco13310-bib-0041","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: A case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"2021122510445623600_onco13310-bib-0042","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122510445623600_onco13310-bib-0043","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510445623600_onco13310-bib-0044","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"281","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510445623600_onco13310-bib-0045","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1097\/MPH.0000000000000364","article-title":"Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma","volume":"37","author":"Modak","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122510445623600_onco13310-bib-0046","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"Mendez-Martinez","year":"2019","journal-title":"Retina"},{"key":"2021122510445623600_onco13310-bib-0047","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","article-title":"MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects","volume":"65","author":"Urner-Bloch","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122510445623600_onco13310-bib-0048","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamaophthalmol.2017.0275","article-title":"MEKanisms of a serous complication","volume":"135","author":"Montana","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2021122510445623600_onco13310-bib-0049","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: A new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"2021122510445623600_onco13310-bib-0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/e1109\/41919407\/oncolo_25_7_e1109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/e1109\/41919407\/oncolo_25_7_e1109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T05:47:49Z","timestamp":1640411269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/7\/e1109\/6443557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0069","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,4,22]]}}}